我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
12
0 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
2000
已完成
9
75.0%
Unknown
3
25.0%
暂无批准数据
- Mauna Kea Technologies obtained NMPA approval for its Cellvizio Gen 3 confocal laser endomicroscopy platform in China following a three-year certification process. - The five-year registration authorizes use of the advanced imaging system with the company's full range of confocal probes for real-time cellular visualization during endoscopic procedures. - The approval reopens the Chinese market for Mauna Kea independently of its joint venture with Tasly, positioning the company to capitalize on strong demand for precision diagnostic technologies in interventional endoscopy.
